### General Comments & Additional Information

**Clinical Info:** NORMAL REPORT

**Ordered Items**
Dabigatran

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran</td>
<td>75.8</td>
<td>01</td>
<td>ng/mL</td>
<td>64.0 - 443.0</td>
<td>01 BN LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD</td>
</tr>
</tbody>
</table>

Plasma concentrations of total dabigatran following 150 mg twice daily dosing of dabigatran etexilate were as follows (19):

- **Peak:** 184.0 Mean Range (+/- 2SD)
- **Trough:** 90.0 31.0 - 225.0

Peak levels should be drawn 2-3 hours after oral dosing. Trough levels are drawn 12 hours after oral dosing. Steady state is attained after 3 days of twice daily treatment. The peak and trough ranges are obtained from the RE-LY study and represent the median (5th and 95th percentiles).


**Comments:**

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
General Comments & Additional Information
Clinical Info: ABNORMAL REPORT

Ordered Items
Dabigatran

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran</td>
<td>453.2</td>
<td>01</td>
<td>ng/mL</td>
<td>64.0 - 443.0</td>
<td></td>
</tr>
</tbody>
</table>

Plasma concentrations of total dabigatran following 150 mg twice daily dosing of dabigatran etexilate were as follows (19):

- Mean:
  - Peak: 184.0
  - Trough: 90.0
- Range (+/- 2SD):
  - Peak: 64.0 - 443.0
  - Trough: 31.0 - 225.0

Peak levels should be drawn 2-3 hours after oral dosing. Trough levels are drawn 12 hours after oral dosing. Steady state is attained after 3 days of twice daily treatment. The peak and trough ranges are obtained from the RE-LY study and represent the median (5th and 95th percentiles).


Comments:
- This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

01    BN    LabCorp Burlington
1447 York Court, Burlington, NC 27215-3361
Dir: Sanjai Nagendra, MD

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762